Clinical trials: Constipation Predominant Irritable Bowel Syndrome
- Condition Constipation Predominant Irritable Bowel Syndrome
- Funder type Industry (pharma, biotech, devices)
Constipation-predominant IBS (IBS-C)
Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)
The objective of this Phase II trial is to test the NTX-1 Fiber in patients with constipation-predominant IBS (IBS-C) and determine if it can reduce symptoms, beneficially modify gut microbiota composition, and improve gut milieu…
- Trial name
- NCT02144753
- Testing
- NTX-1, psyllium (15 g)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Nutrabiotix, LLC
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Constipation - Functional, Constipation-predominant Irritable Bowel Syndrome
MOWOOT Device Treatment for Adults With Chronic Constipation
The primary objective is to compare the effectiveness of the experimental Intermittent Colonic Exoperistalsis (ICE) treatment with MOWOOT, with the active control of trans-anal irrigation (TAI) as standard-of-care.
- Conditions
- Constipation - Functional, Constipation-predominant Irritable Bowel Syndrome, Constipation Chronic Idiopathic, Constipation; Neurogenic
- Trial name
- MOTACC (NCT04666155)
- Testing
- Intermittent Colonic Exoperistalsis with MOWOOT device, Standard of care with Trans-Anal Irrigation
- Where
- 3 sites in United Kingdom
- Volunteers
- 86 people
- Sponsor
- usMIMA S.L.
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome
Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)
Study is to assess the effectiveness of TC-6499 in the treatment of constipation predominant IBS patients over a 28-day period.
- Trial name
- NCT01149200
- Testing
- TC-6499
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Irritable Bowel Syndrome With Constipation
A Multistrain Probiotic in Patients With Irritable Bowel Syndrome With Predominant Constipation
Probiotics efficacy is mainly assessed by subjective endpoints such as the FDA responder rate or global relief, which partly explain contradictory results obtained in clinical trials with probiotic bacteria.
- Trial name
- EPORE (NCT04997057)
- Testing
- Probiotics mixture
- Where
- France
- Volunteers
- 80 people
- Sponsor
- CEN Biotech
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Constipation Predominant Irritable Bowel Syndrome
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III…
- Trial name
- NCT01923428
- Testing
- AZD1722
- Where
- 4 sites in United States
- Volunteers
- 356 people
- Sponsor
- Ardelyx
Constipation Predominant Irritable Bowel Syndrome
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for…
- Trial name
- NCT01340053
- Testing
- RDX5791
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Ardelyx
Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
- Trial name
- NCT00171431
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Constipation-predominant Irritable Bowel Syndrome
Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype
The main objective is to assess the effect of an 8-week daily supplementation with IbSium® (probiotic yeast Saccharomyces cerevisiae CNCM I-3856) on the improvement gastro-intestinal disorders associated to the type C IBS…
- Trial name
- IBS-GO (NCT03150212)
- Testing
- Saccharomyces cerevisiae CNCM I-3856
- Where
- 5 sites in France
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Lesaffre International
Constipation Predominant Irritable Bowel Syndrome
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria.
- Trial name
- T3MPO-3 (NCT02727751)
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Ardelyx
IBS, Constipation Predominant
The Beneficial Effects on the Intestinal Function of a Food Supplement Based on an Extract of Green Tea and a Pool of Probiotics in Subjects With Irritable Bowel Syndrome With Predominance of Constipation
The study will aim to evaluate the effectiveness of the use of a food supplement, based on a green tea extract (Camellia sinensis (L.) Kuntze - folium) and a pool of probiotics (L. plantarum, L. rhamnosus and B. animalis subsp.
- Trial name
- NCT07094035
- Testing
- food supplement based on a mixture of green tea extract and a pool of probiotics.
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Adamas Biotech S.r.l.
Irritable Bowel Syndrome
DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is the most commonly identified functional gastrointestinal disorder, affecting 10-20% of the population in the Western world, seen predominantly in females and with a negative impact on quality of…
- Trial name
- NCT00220090
- Testing
- dexloxiglumide
- Where
- United Kingdom
- Sponsor
- Rottapharm
Constipation Predominant Irritable Bowel Syndrome
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
This phase 3, 26-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of one dose of Tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as…
- Trial name
- T3MPO-2 (NCT02686138)
- Testing
- Tenapanor
- Where
- 117 sites in United States
- Volunteers
- 593 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome With Constipation (IBS-C)
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the efficacy and safety of ASP0456 in patients with constipation predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT02316899
- Testing
- linaclotide
- Where
- 61 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Inc
Constipation-Predominant Irritable Bowel Syndrome
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT00607971
- Testing
- Renzapride
- Where
- 126 sites in United States
- Volunteers
- 939 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS.
- Trial name
- NCT00258193
- Testing
- MD-1100 Acetate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
- Trial name
- NCT00268879
- Testing
- Renzapride
- Where
- United Kingdom
- Volunteers
- 1,821 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms
- Trial name
- NCT01027260
- Testing
- Itopride HCI 50 mg, Itopride HCI 100 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 268 people
- Sponsor
- Abbott